Standard Packaging Crucial for Regulation of Smokeless Tobacco: Experts

Sep.06.2022
Standard Packaging Crucial for Regulation of Smokeless Tobacco: Experts
Bangladesh health experts emphasize the importance of standard packaging for regulating new smokeless tobacco products.

Experts in Bangladesh’s healthcare industry have stated that standard packaging plays a crucial role in regulating the consumption of new and smokeless tobacco products. Smokeless tobacco products pose a harmful threat to public health that is just as significant as the control of cigarette and alcohol consumption, the experts say.


On Monday, during a seminar held at the Six Seasons Hotel in the capital, it was stated that approximately 22 million people in Bangladesh consume smokeless tobacco, which accounts for 58% of the total tobacco consumption in the country.


During a keynote speech at an event organized by the ARK Foundation, York University, and the Health Economics Research Network (HERN), Kamran Siddiqui, Professor of Global Public Health at the Department of Health Sciences at York University, stated that Bangladesh, India, and Pakistan have unusually high rates of smokeless tobacco usage and prevalence in the world.


Despite a slight decline in cigarette consumption rates in Bangladesh over the past few years, the use of smokeless tobacco has remained almost unchanged. Therefore, now is a crucial time to focus on controlling this type of product. This was emphasized by Professor Kamran at a seminar titled "Addressing Smokeless Tobacco Control Policy in Bangladesh.


Kamran Siddiqui has presented several suggestions to control the use of non-combustible tobacco products:


The removal of seasoning products restrictions, the development of standards and monitoring of tobacco-specific nitrosamines (TSNAs), the introduction of retail licenses and viable alternatives, a strict ban on online or social media advertising, community authorization to enforce the ban on sales to minors, increasing taxes, and linking the minimum price to a pack of 20 cigarettes were discussed at an event hosted by Professor AHM Enayet Hossain, former Director General of the Department of Medical Education, with Professor Shakil Ahmed, Director of the National Tuberculosis Control Program, serving as the keynote speaker.


Dr. Syed Mahfuzul Huq, a national expert of the World Health Organization (WHO), participated as a panelist in a project led by Rumana Huque, Executive Director of the ARK Foundation and Professor of Economics at Dhaka University.


During a seminar, a spokesperson revealed that 84% of smokeless tobacco products in Bangladesh do not have appropriate picture health warnings on their packaging. Even if they do have picture health warnings, they do not comply with regulations. They also pointed out that 30% of the packages have no health warnings at all. In neighboring India, the percentage is only 7%.


Furthermore, 16% of tuberculosis patients in Bangladesh are also tobacco consumers. Therefore, experts suggest that controlling tobacco consumption could play a significant role in controlling tuberculosis.


Statement


This article is compiled from third-party information and is intended for industry professionals for the purpose of exchanging knowledge and insights.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of its contents. The translation of this article is solely for industry-related exchange and research purposes.


Due to limitations in translation ability, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS aligns completely with the Chinese government's remarks and positions regarding any domestic, Hong Kong, Macao, Taiwan, or international affairs.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19